Compare Sana Biotechnology Inc (SANA) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Williams Companies Inc — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Williams Companies Inc trades at $72.67 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 105.7× Sana Biotechnology Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Williams Companies Inc for 58 Days on average.
| SANA | WMB | |
|---|---|---|
Market Cap | $836.71M | $88.48B |
Volume | 4,507,444 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $5.92 | $79.40 |
52-Week Low | $2.68 | $56.51 |
Typical Hold Time | 23 Days | 58 Days |
Enterprise Value | $749.96M | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
WMB trades at $72.34, up 1.23% with a bullish technical signal. The company shows strong profitability with 25.18% net income margin and 24.02% ROE, though valuation ratios appear elevated with P/E of 28.82. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. Natural gas demand growth from AI data centers provides strategic positioning for future revenue growth.
WMB offers attractive dividend yield with 79% analyst buy ratings and $87.27 consensus target, suggesting 21% upside. Key risks include energy market volatility and high debt levels at $24.74 billion long-term debt. The stock presents opportunity for income investors seeking exposure to resilient midstream energy infrastructure with fee-based revenue model.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
